Original Title: Estimulación del nervio vago para epilepsia resistente

Authors' recommendations: High-quality evidence suggests that vagus nerve stimulation (VNS) results in a higher net benefit because it reduces the number of epileptic crises >50% in approximately half of adults and children with drug-resistant epilepsy. It also improves the Depression Scale score. VNS may also reduce the rate of sudden death in epilepsy. No serious adverse effects have been reported. The clinical practice guidelines consulted recommend vagus nerve stimulation in adults and children with drug-resistant epilepsy who are not eligible for surgical resection. Most of the funders consulted cover this technology and in Argentina, reimbursement is possible in those over 12 years old. The economic evaluations consulted indicate that this is a cost-effective technology but its coverage depends on the threshold of each country. No local cost-effectiveness studies have been found; thus until now, this dimension remains uncertain.

Project Status: Completed

Year Published: 2022

URL for published report: https://www.iecs.org.ar/publicacion/?id=21782

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)